A cyclical downturn in construction/industrial end-markets against a still-mature top line
One-line thesis. This is a brand-new, much smaller DuPont: after spinning off its Electronics business (Qnity) in November 2025 and selling Aramids in April 2026, the "RemainCo" is a ~$7B-revenue specialty-materials company in healthcare, water, construction and industrial — growing organic sales ~2–4% with rising EBITDA margins (~24%), trading around 12× EV/EBITDA. At ~$141 base-case fair value it is roughly fairly priced: a decent, de-levered cash generator, but not cheap enough or fast enough to earn a Buy, and there is no expert conviction behind it.
◆ Synthos call — AvoidDD's problem is the business, not the price — weak growth and/or a deteriorating trajectory; a cheaper quote alone won't change our mind.
Downside Risk (lower = safer)
5/10 · Moderate
Modest 1.4× net-debt/EBITDA and 12× EV/EBITDA, but cyclical end-markets, a GAAP loss year, C+ letter rating and a pending reverse split add noise.
Growth Quality
4/10 · Moderate
~4% organic revenue growth with expanding EBITDA margins (~24%), but low-6% ROIC and a cyclical Industrials leg cap the quality.
Exponential Potential
2/10 · Low
Post-spin specialty-materials compounder growing ~4%/yr with no acceleration — a steady cash machine, not an exponential.
What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Buy — CoreOwn it as a foundation — start or add now, size it for years, let dips be gifts.
Buy — TacticalGood price + confirmed trend + a defined exit — buy the setup, not a marriage.
WatchWe want the business, just not at this price/setup — act only when the listed trigger hits.
HoldFine to keep if you own it — no reason to buy more; new money does better elsewhere.
AvoidDon't own it — the problem is the business or the expectations, so a cheaper price won't fix it.
In plain English
DuPont used to be a sprawling chemicals giant. In late 2025 it split itself up — it spun off its electronics/semiconductor arm into a separate company (Qnity) and sold another business (Aramids). What's left is a smaller company that makes specialized materials for healthcare, water purification, construction, and industry — think medical packaging, water filters, and high-performance materials.
The leftover business is steady but slow: sales grow only a few percent a year, though it keeps a healthy chunk of each dollar as profit and doesn't carry much debt. On the numbers we trust most, the stock trades at roughly what it's worth — not a bargain, not wildly overpriced.
Our verdict is Watch: nothing is broken, but nothing is compelling either. Here's what the three scores mean in plain terms:
Downside Risk 5/10 (middle). Financially sound and not heavily indebted, but its customers are in cyclical industries (like construction) that slow down when the economy does.
Growth Quality 4/10 (below average). It grows slowly and its profits on the money invested are only so-so.
Exponential Potential 2/10 (low). This is a slow-and-steady business. Don't expect it to double quickly.
The one big worry: a slump in construction and industrial demand would hit sales and profits at the same time, and there's no fast-growing engine to offset it.
Two honesty flags a beginner should know: (1) The Wall-Street "price target" in our data feed (~$56) is left over from before the split and doesn't match today's $140 stock — we ignore it. (2) Management has proposed a reverse stock split (combining shares), which would raise the per-share price mechanically without changing what the company is worth.
Solid = price · dashed = 50-day average · dotted = 200-day average · amber = 52-week high/low. Price above both averages is an uptrend.
Bollinger Bands 20-day average ± 2 standard deviations
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Blue crossing above amber (bars flip green) = momentum turning up; below (bars red) = turning down. Bar height = the size of that gap.
Relative performance vs S&P 500 & its sector (XLB (sector)), set to 100 a year ago
Solid = DD · dashed = S&P 500 · dotted = XLB (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Key stats an RIA wants
Price$139.91
Market cap$19B
P/E trailing6×
P/E FY26E / FY27E20× / 18×
EV / Sales2.2×
EV / EBITDA12.2×
Gross margin33.8%
Net margin-0.3%
Dividend yield1.65%
Beta1.076
52-wk range$88 – $155
RSI(14)49
50 / 200-DMA$142 / $129
12-mo return+56% (SPY +21%)
Street target$56 ($52–$60)
Analyst grades24 Buy · 16 Hold · 1 Sell
FMP ratingC+
Next earnings2026-08-05
What the experts actually said 0 traceable claims on DD · showing the highest-conviction voices
Every claim reconciles to a real claim_id in the Synthos knowledge base — this is the evidence the verdict is built on, not vibes. Management (the company itself) is shown but half-weighted; one cautionary voice is included on purpose.
1. What it is
DuPont de Nemours (NYSE: DD) is a global specialty-materials company headquartered in Wilmington, Delaware, led by CEO Lori Koch. The company you see today is not the company of a year ago. Two structural events reshaped it:
The Qnity spin-off (Nov 2025): DuPont separated its large Electronics & Industrial (semiconductor/advanced-materials) business into an independent public company, Qnity. That is why FY2025 continuing-operations revenue collapses to $6.85B from FY2024's $12.39B — the Electronics revenue left with the spin and is reported as discontinued operations.
The Aramids divestiture (Apr 1, 2026): DuPont sold its Aramids (Kevlar/Nomex-type) business for ~$1.2B cash plus a note and equity stake; it is also treated as discontinued operations.
The RemainCo now reports in two segments (per the Q1'26 release):
Healthcare & Water Technologies — medical packaging, biopharma materials, water purification/separation. Q1'26 sales $806M, 30.3% EBITDA margin (+110 bps YoY), organic +3%. The higher-quality, less-cyclical leg.
Diversified Industrials — Building Technologies and Industrial Technologies (aerospace, automotive, printing/packaging). Q1'26 sales $875M, 22.9% EBITDA margin, organic ~flat — dragged by weak construction markets.
Geographic revenue (FY2025 continuing ops, from filings): U.S. & Canada $3.42B (50%) · Asia-Pacific $1.64B · EMEA $1.47B · China $0.71B · Latin America $0.33B. Roughly half US, half international — typical for specialty chemicals.
Note on the older segment tables in the data feed (Electronics & Industrial $5.9B, Water & Protection $5.4B, etc.): those are the pre-spin structure and no longer describe the company. We use the Q1'26 two-segment view.
2. The expert thesis
There is no expert coverage of DuPont in the Synthos knowledge base.total_claims = 0; zero net-bullish voices; no cautionary voice either. None of the investor-panel voices Synthos tracks have said anything traceable about DD.
Accordingly, this note carries no conviction premium and cites no claim_ids — to do so would be fabrication, which the house standard forbids. The verdict below rests entirely on the reported fundamentals (FMP filings), management's own guidance (half-weighted), and quantitative valuation. Readers should weight this as a fundamentals/quant call, not an expert-backed one. For a name this freshly restructured, the absence of a distilled expert view is itself information: the story is too new and too corporate-action-driven for the panel to have formed one.
3. Synthos scores & the Bull / Base / Bear cases
The one-glance judgment — three scores, 0–10, each anchored to real metrics:
Score
0–10
The read
Downside Risk(lower = safer)
5 · Moderate
Net-debt/EBITDA 1.4×, current ratio 2.7×, and a reasonable 12× EV/EBITDA are supportive; but cyclical construction/industrial exposure, a GAAP net loss in FY25 (spin/impairment charges), a C+ letter rating (weak ROE/ROA), and a pending reverse split add uncertainty. Beta 1.08.
Growth Quality
4 · Below-average
Organic sales ~2–4%, EBITDA margin expanding (~24%, +110–230 bps YoY), but ROIC ~6%, TTM ROE negative, and half the business is cyclical Industrials. The Healthcare/Water leg is genuinely good; the whole is average.
Exponential Potential
2 · Low
~4% forward revenue CAGR (FY25→FY29E $6.85B→$8.07B), no acceleration — organic growth is flat-to-low-single-digit. A mature specialty-materials compounder, not an exponential.
The three cases (our own EV/EBITDA-based scenario model — assumptions shown; each target is a ~12–18-month fair value). We do not attach probabilities; the cases bound the range and the scores summarize them. Because the FMP per-share EPS estimates are distorted by the restructuring (see §6), we value off EV/EBITDA, the cleanest cross-cyclical lens, then bridge to equity per share (net debt $2.44B, ~137M shares).
Case
Key assumptions
Fair value
Bull
Healthcare/Water re-rates the mix; construction recovers; FY28 EBITDA ~$1.95B earns a ~13.5× multiple as a de-levered, cleaner compounder.
~$174 (+24%)
Base(our anchor)
Guidance roughly holds; FY27 operating EBITDA ~$1.81B at a fair ~12× for slow-growth specialty chem.
Synthos fair value = the base case, ~$141 (+1%), with the full $105–$174 span as the honest range. The stock is trading right at our base-case fair value — the market is pricing this roughly correctly. We discard the FMP Street target (~$56) entirely: it is a stale, pre-restructuring number attached to a post-restructuring $140 tape and would be misleading to headline. This is a tracked call — the Forecaster Scorecard grades it once it matures.
4. Exponential Potential
Synthos separates compounders (durable returns on capital) from exponentials (accelerating multi-baggers). DuPont is neither an exponential nor, yet, a proven compounder — it is a re-based cyclical:
Acceleration (2nd derivative):flat. Q1'26 organic +2%, guided to ~3% in Q2 and ~4% for the year — steady, not accelerating. Building Technologies is declining on weak construction; the growth comes from Healthcare and aerospace/auto within Industrials.
Room to run: end-markets (medical packaging, water, construction materials) are large but mature and contested; there is no winner-take-most TAM expansion here. At ~$19B market cap the name could re-rate modestly, but there is no structural runway for a multibagger.
Reinvestment runway: capex is light (~$102M in Q1'26, ~$333M FY25, ~2% of sales) and FCF conversion is solid (65% in Q1'26) — this is a cash-return story (dividend + buyback), not a high-reinvestment compounding story.
Exponential Potential: Low (2/10). Own DD, if at all, for steady cash generation and a possible mix re-rate, not for growth. This is the honest framing: a defensible, de-levered materials business whose ceiling is a modest multiple expansion, not exponential earnings.
Read these on a continuing-operations basis; headline GAAP is badly distorted by the spin.
Revenue: FY25 continuing-ops $6.85B (vs $12.39B FY24 pre-spin — the drop is the Qnity separation, not a demand collapse). Q1'26 net sales $1.68B, +4% reported / +2% organic.
Earnings: FY25 GAAP net income was −$779M (a loss) — driven by an −$836M discontinued-operations charge (spin/impairment); continuing-ops net income was positive at $98M. This is why the trailing P/E (−777×) and adjusted P/E (~59×) are both meaningless here. Q1'26 GAAP income from continuing ops $150M (+88% YoY); adjusted EPS $0.55, +53% YoY.
Cash flow: FY25 operating CF $1.41B, capex −$333M, FCF ~$1.08B (5.7% FCF yield). Q1'26 transaction-adjusted FCF $147M at 65% conversion — a genuine improvement off a weak base.
Balance sheet: total debt $3.19B, cash $757M, net debt $2.44B, net-debt/EBITDA ~1.4× — down sharply from ~2.0× post-spin deleveraging. Current ratio 2.7×, interest coverage ~5.2×. Investment-grade and comfortable.
Capital returns: $500M buyback in FY25, a further $275M accelerated share repurchase announced with Q1'26, and a ~1.65% dividend yield ($2.31/sh TTM). Cash is being returned, consistent with the low-growth profile.
6. Valuation — priced in or room?
The per-share earnings multiples in the data feed are not trustworthy for this name, and we say so. Trailing P/E is negative (FY25 GAAP loss); "adjusted" P/E on management's $2.35–2.40 FY26 guidance is ~59× — but that figure sits against a pending reverse stock split (1-for-2 to 1-for-4) and a share/estimate basis that FMP has not cleanly restated post-spin (its est block still shows FY26 EPS ~$7.16, which does not reconcile to management's ~$2.37 adjusted guidance). We therefore anchor on enterprise value, which is unaffected by share-count games:
EV/EBITDA ~12.2× TTM (EV $21.3B / EBITDA ~$1.74B) — a fair, middle-of-the-fairway multiple for a slow-growth specialty-chemicals company. On FY26E EBITDA (~$1.75B) it is ~12×; on FY27E (~$1.81B) ~11.8×.
EV/sales 2.2×, FCF yield 5.7%, price/book 1.36× — none of these scream cheap or expensive.
Reverse-EV read: at $140 the market is paying ~12× for a business guided to ~4% organic growth with expanding margins. That is a fair price — neither the deep discount that would make this a Buy nor the premium that would make it an Avoid.
Street targets (context only): the FMP consensus target of ~$56 is stale/pre-restructuring and internally inconsistent with a $140 tape and a "Buy" grade tally (24 Buy / 16 Hold / 1 Sell) — we do not use it as an anchor and flag it as a data artifact. Our EV/EBITDA-derived base-case fair value is ~$141, essentially where the stock trades. Not a value buy; fairly valued.
7. Technicals (from the tech block)
Trend: mixed-to-up. $139.91 sits above the 200-DMA ($128.80) but below the 50-DMA ($142.45) — a short-term pullback within a longer uptrend.
Location:−9.5% off the 52-week high ($154.59), +59% off the 52-week low ($87.75). Max drawdown from peak −9.5% — orderly, not broken.
Momentum: RSI(14) 49 — neutral, neither overbought nor oversold. MACD −1.45 (mildly negative) — near-term momentum has cooled.
Relative strength:+56% 12-mo vs SPY +21% (strong 1-yr outperformance, largely the spin/re-rate), but only +0.9% 3-mo vs SPY +13.7% — it has lagged badly the last quarter as the post-spin excitement faded.
Read: technicals are neutral. The 12-month chart is strong but the recent 3-month lag and sub-50-DMA price say momentum has stalled. No urgency to buy or sell on the tape — consistent with a Watch.
8. Moat & competitive position
DuPont's moat is moderate and segment-specific: durable in Healthcare/Water (regulated, spec'd-in medical-packaging and water-purification materials with switching costs and 30%+ margins), thinner in Diversified Industrials (more cyclical, more commoditized construction and industrial materials). The company competes on formulation know-how, regulatory qualifications, and brand (Tyvek, Liveo, water technologies), not on scale-cost leadership. Post-spin it is smaller and more focused, which is a plausible quality upgrade — but it also shed its highest-growth (electronics/semiconductor) leg with Qnity.
Peer set (from the data feed, market cap): Dow $20.0B (the direct legacy sibling), LyondellBasell $17.2B, IFF $21.4B, Albemarle $16.0B, SQM $20.8B, CF Industries $17.0B, RPM $14.2B, Reliance $19.0B, Cemex $17.8B. Note the FMP peer list is a broad basic-materials basket (it even includes a gold miner, Alamos) — the truest comps are the specialty/diversified chemicals names (Dow, LYB, IFF, RPM). Against those, DD's ~12× EV/EBITDA and ~24% EBITDA margin are middle-of-pack — richer than commodity chem (Dow/LYB), cheaper than premium specialty (RPM).
9. Management, capital allocation & guidance
Capital allocation: disciplined and shareholder-friendly — post-spin deleveraging (net-debt/EBITDA to ~1.4×), a $500M FY25 buyback plus a $275M accelerated repurchase announced with Q1'26, a maintained dividend (~1.65% yield), and light capex (~2% of sales). Appropriate for a low-growth cash generator.
Insider activity: the sampled Form 4s (filed 2026-06-02, transactions late May 2026) are almost entirely routine — CEO Lori Koch and CFO Antonella Franzen show tax-withholding "F-InKind" dispositions (not open-market sales) around $48, and several directors received awards (acquisitions). Note the ~$48 price on these filings vs the $140 quote is another sign of the share-basis/restructuring distortion in the feed. No alarming cluster of discretionary insider selling.
Management's own guidance (half-weighted — their self-interested words): the SEC 8-K (Q1'26 earnings release, filed 2026-05-05) is a genuine earnings release and gives dated forward guidance. Management raised full-year 2026 guidance: net sales $7.155–$7.215B, operating EBITDA $1.730–$1.760B, adjusted EPS $2.35–$2.40; for Q2'26, net sales ~$1.8B, operating EBITDA ~$430M, adjusted EPS ~$0.59. FY26 assumes ~4% organic growth (incl. ~1% pricing to offset Middle-East-conflict input-cost inflation) plus an interest-income benefit from the Aramids sale. CEO Koch cited "organic growth, margin expansion, and double-digit adjusted EPS growth." Treat as management talking its book — half-weight. It is, however, internally consistent with the reported Q1'26 beat (adj EPS $0.55 vs $0.36 prior year) and is the most reliable forward anchor we have (more so than the distorted FMP EPS estimates).
10. Catalysts & what to watch
Next earnings: 2026-08-04 (Q2'26; management guides adj EPS ~$0.59, net sales ~$1.8B, operating EBITDA ~$430M). Watch organic growth (guided ~3%) and whether construction stabilizes.
Reverse stock split: management is seeking approval at the 2026 Annual Meeting for a 1-for-2 to 1-for-4 reverse split. Mechanically neutral to value but changes the per-share optics and the data feeds — watch for the ratio and effective date.
Construction/industrial demand: Building Technologies is the current drag; a turn here is the swing factor for the Diversified Industrials segment.
Healthcare/Water momentum: continued 30%+ margins and high-single-digit organic growth in medical packaging/biopharma would support a mix re-rate (the bull case).
Post-spin capital returns: execution of the $275M ASR and any further buyback/dividend action.
Thesis tripwires (what would change the call): organic sales turning negative for two consecutive quarters; EBITDA-margin reversal below ~22%; net-debt/EBITDA rising back above ~2×; or, on the upside, a sustained Healthcare/Water re-rate that would argue for an upgrade from Watch toward Buy — Tactical.
11. Key risks
Cyclicality (structural): roughly half the business (Diversified Industrials, incl. construction) is economically sensitive; a downturn hits volume and mix simultaneously. Construction is already weak.
Slow organic growth: ~2–4% leaves little cushion; DD must deliver on margins and buybacks to move EPS.
Restructuring/complexity overhang: back-to-back spin (Qnity) and divestiture (Aramids) plus a pending reverse split make the reported financials and third-party data feeds hard to read — a source of mispricing and confusion (as the stale ~$56 target and ~$48 insider prices show).
No expert conviction / no moat premium: with zero KB coverage, there is no informed second opinion supporting the name — the call is quant/fundamentals only.
Input-cost / geopolitical inflation: management flagged Middle-East-conflict-driven input-cost inflation being passed through via ~1% pricing — a margin risk if pricing power fades.
Data-quality risk: the FMP EPS estimates and price target do not reconcile to management's own guidance; anyone anchoring on those figures would badly misjudge the stock.
12. Verdict, position sizing & monitoring
Watch. Post-restructuring DuPont is a cleaner, de-levered, ~$7B-revenue specialty-materials business with expanding EBITDA margins (~24%), solid FCF (5.7% yield), a modest 1.4× net-debt/EBITDA, and shareholder-friendly capital returns. But it grows only ~4% organically with no acceleration, half its revenue is cyclical, it posted a GAAP loss year on spin charges, carries a middling C+ quality rating, and — critically — trades right at our ~$141 base-case fair value. There is no expert conviction behind it and no valuation discount to create one. That combination is the textbook definition of a Watch: nothing broken, nothing compelling.
Sizing: not a Buy today. If held for the dividend/cash-return profile, keep it small (~1–2%) in a cyclical-materials sleeve. New money is better deployed on a pullback toward the low-$120s (nearer the 200-DMA and our bear/base midpoint) or on evidence of a Healthcare/Water-led re-rate.
Monitoring: re-underwrite on the §10 tripwires; formal re-score each earnings print, and re-check the data feed after the reverse split so the per-share math stays honest.
Single biggest risk: a cyclical downturn in construction/industrial demand against a top line that is only growing low-single-digits.
An upgrade to Buy — Tactical would require either a clear valuation discount (EV/EBITDA toward ~10× / price toward the low-$120s) or a demonstrated, sustained mix shift toward the higher-margin Healthcare/Water franchise.
Provenance & disclosures
Traceability:0 KB claims, breadth 0 — DuPont has no expert coverage in the Synthos knowledge base. No claim_ids are cited because none exist; this note is explicitly fundamentals- and quant-driven. Fabricated conviction is structurally impossible (claim-ID reconciliation) and none is claimed here.
Data as-of: fundamentals 2026-03-31 (Q1'26) · estimates & prices 2026-07-02/03 · management guidance from the SEC 8-K earnings release filed 2026-05-05. Forward figures are analyst consensus (FMP) or management guidance, labeled as estimates.
Data-quality caveat (important): DuPont's Nov-2025 Qnity spin-off, Apr-2026 Aramids divestiture, and a pending reverse stock split distort several third-party fields — the FMP price target (~$56), the FMP forward EPS estimates (~$7.16 FY26), and the ~$48 insider-transaction prices all fail to reconcile to the current ~$140 tape and management's ~$2.37 adjusted-EPS guidance. We valued off EV/EBITDA to sidestep this and discarded the stale price target as an anchor.
Management caveat: management's FY26 guidance is its own self-interested view, half-weighted by design.
Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").